Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069251 · ClinicalTrials.gov registry record · Phase 2
Bupropion for the Treatment of Methamphetamine Dependence - 1
A Phase 2 study of Amphetamine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 5
- Study locations
NCT00069251 is a Phase 2 study of Amphetamine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 150 participants, above the 62-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (142% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT00069251, a Phase 2 study of Amphetamine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence
Conditions Studied
Interventions
- DRUG Bupropion
Study Locations (5)
California
- Matrix Institute on Addictions - Costa Mesa
- South Bay Treatment Center - San Diego
Hawaii
- Pacific Addiction Research Center - Honolulu
Iowa
- Powell Chemical Dependency Center - Des Moines
Missouri
- University of Missouri - Kansas City - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069251
The ClinicalTrials.gov registry entry for NCT00069251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (142% higher). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amphetamine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Bupropion is the first listed.
NCT00069251 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Hawaii, Iowa.
Frequently Asked Questions
What is clinical trial NCT00069251 about?
NCT00069251 is a clinical study titled "Bupropion for the Treatment of Methamphetamine Dependence - 1". The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence
What is the current status of trial NCT00069251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-07. Estimated completion is 2005-06.
What conditions does trial NCT00069251 study?
This clinical trial studies the following conditions: Amphetamine-Related Disorders.
What interventions are being tested in trial NCT00069251?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT00069251?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00069251 being conducted?
This trial has 5 study locations across California, Hawaii, Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amphetamine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
COMPLETED · Phase 2
-
Tyrosine for Methamphetamine Dependence - 1
COMPLETED · Phase 2
-
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
COMPLETED · Phase 2
-
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
RECRUITING · Phase 1
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.